Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50929
Name mucosal melanoma
Definition A melanoma that has_material_basis_in melanocytes located_in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer melanoma mucosal melanoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT C443S Imatinib mucosal melanoma sensitive detail...
BRAF V600L Dabrafenib + Trametinib mucosal melanoma predicted - sensitive detail...
KIT N822K Avapritinib mucosal melanoma predicted - sensitive detail...
KIT exon17 Avapritinib mucosal melanoma predicted - sensitive detail...
EML4 - ALK Crizotinib mucosal melanoma sensitive detail...
EML4 - ALK Ceritinib mucosal melanoma sensitive detail...
EML4 - ALK Entrectinib mucosal melanoma sensitive detail...
EML4 - ALK ASP3026 mucosal melanoma sensitive detail...
EML4 - ALK Alectinib mucosal melanoma sensitive detail...
NRAS Q61H Trametinib mucosal melanoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02645149 Phase II Trametinib Pazopanib Ceritinib Ribociclib + Trametinib Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) Recruiting AUS 0
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Active, not recruiting USA 0
NCT02818023 Phase I Cobimetinib + Pembrolizumab + Vemurafenib Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Terminated USA 0
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT02978443 Phase II Ipilimumab + Nivolumab A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Unknown status USA 0
NCT03220009 Phase II Ipilimumab + Nivolumab Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn USA 0
NCT03235245 Phase II Binimetinib + Encorafenib Ipilimumab + Nivolumab Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) Recruiting ITA | GBR | FRA | ESP | DEU | BEL 2
NCT03241186 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Active, not recruiting USA 0
NCT03313206 Phase II Pembrolizumab Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ) Recruiting FRA 0
NCT03340129 Phase II Ipilimumab + Nivolumab Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) Recruiting AUS 1
NCT03817125 Phase I Nivolumab + SER-401 Vancomycin Nivolumab Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) Completed USA 0
NCT03875079 Phase I Pembrolizumab + RO6874281 A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma Completed USA | FRA | ESP | CAN | BEL | AUS 1
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Recruiting USA 0
NCT04042506 Phase II Nivolumab SBRT as a Vaccination for Metastatic Melanoma Withdrawn USA 0
NCT04139902 Phase II Cobolimab + Dostarlimab-gxly Dostarlimab-gxly PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) Recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04318717 Phase Ib/II Pembrolizumab Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma Recruiting USA 0
NCT04493203 Phase II Axitinib + Nivolumab Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Recruiting USA 0
NCT04551352 Phase I RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Completed USA | ESP | CAN | BEL | AUS 1
NCT04570332 Phase II BO-112 + Pembrolizumab BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203) Active, not recruiting FRA | ESP 0
NCT04577807 Phase II PVSRIPO + unspecified PD-1 antibody PVSRIPO PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma Recruiting USA 0
NCT04830124 Phase II ALKS 4230 Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6) Recruiting USA | ITA | GBR | ESP | CAN | AUS 2
NCT04987996 Phase II Pembrolizumab Belapectin + Pembrolizumab GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients Suspended USA 0
NCT05061134 Phase II Ceralasertib + Durvalumab Ceralasertib A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT05098210 Phase I NeoVax + Nivolumab + Poly ICLC Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer Recruiting USA 0
NCT05111574 Phase II Nivolumab Cabozantinib + Nivolumab Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Recruiting USA | CAN 0
NCT05384496 Phase II Axitinib + Ipilimumab + Nivolumab Axitinib + Nivolumab Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Recruiting USA 0
NCT05415072 Phase Ib/II DYP688 A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Recruiting USA | FRA | ESP | DEU | AUS 2
NCT05428007 Phase II Ipilimumab + Nivolumab and relatlimab-rmbw + Sarilumab Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Recruiting USA 0
NCT05482074 Phase II Olaparib Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Recruiting USA 0
NCT05545969 Phase II Lenvatinib + Pembrolizumab Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM) Not yet recruiting AUS 0